Growth and Leadership With a recent leadership change appointing a new CEO and a history of long-term R&D and clinical testing, Rebion presents a moveable growth path and stability to engage with as a partner for scale and distribution in neuro-visual diagnostics.

Clinical Validation Rebion’s Neural Performance Scanning technology has been developed with major medical institutions and FDA-cleared, suggesting strong clinical credibility to support conversations with hospitals and specialty clinics seeking innovative brain-signal diagnostics.

Targeted Markets The focus on neuro-visual diagnostics and portable point-of-care devices positions Rebion to pursue partnerships with eye care networks, neurology teams, ophthalmology groups, and integrated delivery networks seeking rapid triage and early intervention capabilities.

Strategic Partnerships Founded through collaboration with Johns Hopkins and Harvard, Rebion’s established academic ties open doors for co-development pilots, joint studies, and grant-funded programs with large medical centers and research institutions.

SMB to Mid-Tier Growth Rebion operates with a lean team size and moderate revenue, indicating opportunities for channel partnerships, distributor agreements, and managed service offerings to accelerate adoption through mid-market clinics and specialty practices.